LNLinda J. Noble-Haeusslein

Linda J. Noble-Haeusslein

*This is an algorithmically generated author record based on publicly available information.

Linda J. Noble-Haeusslein has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intraventricular clindamycin enhances interstitial brain fluid drainage and the blood–brain barrier after a traumatic brain injury

    by Landon S. Ashby, Megan G. Crowe, Daveraj Chakravarty, Sanjeev Medam, Gabriel Frampton, Ayesha B. Das, David A. Hormuth, Thomas E. Yankeelov, Vincent Y. C. Wang, Linda J. Noble-Haeusslein, et al.

    Despite advances in the acute clinical management of severe traumatic brain injuries (TBIs), treating injury-derived secondary pathogenesis remains challenging. We demonstrate intracerebroventricular (I.C.V.) administration of clindamycin alleviates TBI secondary pathogenesis in both focal and diffuse murine models of brain injury. I.C.V. administration of clindamycin increased the motility of ependymal cilia, which line the ventricles and spinal canal, by 30 to 60%, which correlated with interstitial brain fluid drainage through the cortex (r > 0.9 Pearson, n = 4 compounds tested). I.C.V. clindamycin treatment post-TBI also restored the blood–brain barrier (BBB), decreased lesion size, and lowered serum levels of glial fibrillary acidic protein by 2.8-fold. Consistent with these data, a novel objective recognition test revealed an improvement in recognition memory in brain-injured mice treated with clindamycin. These collective findings reveal a counterintuitive finding that I.C.V. clindamycin enhances drainage of toxins from the brain while simultaneously restoring the BBB, potentially providing a new solution for alleviating secondary pathogenesis in brain-injured patients.

  • Open Access

    Early Targeting of L-Selectin on Leukocytes Promotes Recovery after Spinal Cord Injury, Implicating Novel Mechanisms of Pathogenesis

    by D. A. McCreedy, S. Lee, C. J. Sontag, P. Weinstein, A. D. Olivas, A. F. Martinez, T. M. Fandel, A. Trivedi, C. A. Lowell, S. D. Rosen, et al.

    L-selectin, a lectin-like receptor on all leukocyte classes, functions in adhesive and signaling roles in the recruitment of myeloid cells from the blood to sites of inflammation. Here, we consider L-selectin as a determinant of neurological recovery in a murine model of spinal cord injury (SCI). Spinal cord-injured, L-selectin knock-out (KO) mice (male) showed improved long-term recovery with greater white matter sparing relative to wild-type (WT) mice and reduced oxidative stress in the injured cord at 72 h post-SCI. There was a partial and transient reduction in accumulation of neutrophils in the injured spinal cords of KOs at 24 h post-injury. To complement these findings with KO mice, we sought a pharmacologic means for lowering L-selectin levels. We found that diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), induced the shedding of L-selectin from the cell surface of myeloid subsets, specifically neutrophils and non-classical monocytes, in the blood and the injured spinal cord. Diclofenac administration to injured WT mice enhanced neurological recovery to a level comparable to that of KOs but did not improve recovery in KOs. While diclofenac treatment had no effect on myeloid cell accumulation, there was a reduction in oxidative stress at 72 h post-SCI. These findings implicate L-selectin in secondary pathogenesis beyond a role in leukocyte recruitment and raise the possibility of repurposing diclofenac for the treatment of SCI.


  • Open Access

    Long-Term Anesthetic-Dependent Hypoactivity after Repetitive Mild Traumatic Brain Injuries in Adolescent Mice

    by Bridgette D. Semple, Raha Sadjadi, Jaclyn Carlson, Yiran Chen, Duan Xu, Donna M. Ferriero, Linda J. Noble-Haeusslein

    Recent evidence supports the hypothesis that repetitive mild traumatic brain injuries (rmTBIs) culminate in neurological impairments and chronic neurodegeneration, which have wide-ranging implications for patient management and return-to-play decisions for athletes. Adolescents show a high prevalence of sports-related head injuries and may be particularly vulnerable to rmTBIs due to ongoing brain maturation. However, it remains unclear whether rmTBIs, below the threshold for acute neuronal injury or symptomology, influence long-term outcomes. To address this issue, we first defined a very mild injury in adolescent mice (postnatal day 35) as evidenced by an increase in Iba-1- labeled microglia in white matter in the acutely injured brain, in the absence of indices of cell death, axonal injury, and vasogenic edema. Using this level of injury severity and Avertin (2,2,2-tribromoethanol) as the anesthetic, we compared mice subjected to either a single mTBI or 2 rmTBIs, each separated by 48 h. Neurobehavioral assessments were conducted at 1 week and at 1 and 3 months postimpact. Mice subjected to rmTBIs showed transient anxiety and persistent and pronounced hypoactivity compared to sham control mice, alongside normal sensorimotor, cognitive, social, and emotional function. As isoflurane is more commonly used than Avertin in animal models of TBI, we next examined long-term outcomes after rmTBIs in mice that were anesthetized with this agent. However, there was no evidence of abnormal behaviors even with the addition of a third rmTBI. To determine whether isoflurane may be neuroprotective, we compared the acute pathology after a single mTBI in mice anesthetized with either Avertin or isoflurane. Pathological findings were more pronounced in the group exposed to Avertin compared to the isoflurane group. These collective findings reveal distinct behavioral phenotypes (transient anxiety and prolonged hypoactivity) that emerge in response to rmTBIs. Our findings further suggest that selected anesthetics may confer early neuroprotection after rmTBIs, and as such mask long-term abnormal phenotypes that may otherwise emerge as a consequence of acute pathogenesis.